CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.
CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.
复制标题
DOI：
10.1158/0008-5472.can-10-1528
复制
发表时间：
2010-10-01
期刊：
影响因子：
11.2
通讯作者：
Reuther GW
中科院分区：
文献类型：
--
作者：
Roll JD;Reuther GW
Expression of cytokine receptor-like factor 2 (CRLF2) has recently been shown to be upregulated as well as mutated in populations of B-ALL, including Down syndrome (DS-ALL) patients, which lack recurring chromosomal translocations. Increased CRLF2 expression associates with JAK2 mutation, a combination that transforms hematopoietic cells, suggesting that mutant JAK2 and CRLF2 may cooperate to contribute to B-ALL formation. Importantly, elevated CRLF2 expression correlates with poor outcome in high-risk B-ALL patients. Therefore, CRLF2 may provide a new prognostic marker for high-risk B-ALL and inhibition of CRLF2/JAK2 signaling may represent a therapeutic approach for this population of ALL patients.
